AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9390614
Drug: I.V. fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V. fentanyl 2 microg/kg, followed by an infusion at the rate of 25 ng x kg(‐1) x min(‐1)
Trial: 9390614
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl injection and infusion at the same administration regimen as Group II
Trial: 9390614
Drug: Bolus injections
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injections of both epidural and intravenous saline, followed by both epidural and I.V. infusions at the rate of 0.2 mL x kg(‐1) h(‐1)
Trial: 3116847
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy after conservative breast surgery plus irradiation
Trial: 21910335
Drug: Thermotherapy combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermotherapy combined with thoracic injection of lentinan
Trial: 16469112
Drug: lumiracoxib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lumiracoxib 400 mg/day (n = 144)
Trial: 16469112
Drug: celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celecoxib 200 mg twice daily (n = 145)
Trial: 12846090
Drug: Combined conservative
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined conservative treatment (antibacterial therapy, transcutaneous laser irradiation of the suprapubic region using intravesical methods)
Trial: 12846090
Drug: Combined conservative
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined conservative treatment plus transurethral resection (TUR) of the urinary bladder mucosa
Trial: 29051989
Drug: Iguratimod 3.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iguratimod 3.125 to 50 mg
Trial: 29051989
Drug: Iguratimod 25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iguratimod 25, 50, 75 mg
Trial: 29051989
Drug: Iguratimod 50
RxNorm normalized name: Iguratimod
DrugBank: Iguratimod (DB12233)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Iguratimod 50 mg (multiple doses)
Trial: 29051989
Drug: Iguratimod 50
RxNorm normalized name: Iguratimod
DrugBank: Iguratimod (DB12233)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Iguratimod 50 mg (single dose)
Trial: 29051989
Drug: Iguratimod 50
RxNorm normalized name: Iguratimod
DrugBank: Iguratimod (DB12233)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Iguratimod 50 mg (fed group)
Trial: 29051989
Drug: Iguratimod 50
RxNorm normalized name: Iguratimod
DrugBank: Iguratimod (DB12233)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Iguratimod 50 mg (fasted group)
Trial: 27077129
Drug: Intracavernous injection
RxNorm normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernous injection of autologous adipose-derived regenerative cells (ADRCs)
Trial: 27077129
Drug: Intracavernous injection
RxNorm normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernous injection of ADRCs in continent men
Trial: 27077129
Drug: Intracavernous injection
RxNorm normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernous injection of ADRCs in incontinent men
Trial: 18303965
Drug: Iloperidone 24
RxNorm normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloperidone 24 mg/day
Trial: 10689152
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated VZV vaccine (Oka 3200)
Trial: 10689152
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated VZV vaccine (Oka 8500)
Trial: 10689152
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated VZV vaccine (Oka 41650)
Trial: 10689152
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Pneumo 23 vaccine)
Trial: 10689152
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated VZV vaccine (all groups)
Trial: 10689152
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated VZV vaccine
Trial: 1286054
Drug: Conventional intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intramuscular meperidine
Trial: 31392213
Drug: Faroese chain
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faroese chain dance intervention (twice‐weekly sessions for 6 weeks, 30 min for first 3 weeks, 45 min for last 3 weeks)
Trial: 26333044
Drug: Secondary prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary prevention using 800 mcg sublingual misoprostol administered to women with postpartum blood loss ≥350 ml
Trial: 26333044
Drug: Universal prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal prophylaxis using 600 mcg oral misoprostol administered to all women during the third stage of labour
Trial: 16638037
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and clomiphene citrate
Trial: 10329808
Drug: Azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine nasal spray 0.14 mg per nostril twice daily
Trial: 10329808
Drug: Cetirizine tablets
RxNorm normalized name: cetirizine Oral Tablet
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetirizine tablets 10 mg every day
Trial: 8534682
Drug: Peritoneal equilibration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritoneal equilibration test (PET) performed twice
Trial: 1938800
Drug: Thioridazine (1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine (1.75 mg/kg/day)
Trial: 29241909
Drug: Hyoscine butyl-bromide
RxNorm normalized name: Butyl Alcohol
DrugBank: Butyl alcohol (DB02145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine butyl-bromide (20 mg in 1 ml)
Trial: 27076940
Drug: S-1 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 with concurrent radiotherapy
Trial: 18089875
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (gemcitabine/platinum without cetuximab)
Trial: 10464830
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol 0.2 mg four times daily
Trial: 8392897
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium 4 mg four times daily
Trial: 7589374
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol 50 micrograms b.i.d.
Trial: 7589374
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol 400 micrograms b.i.d.
Trial: 6268269
Drug: Concomitant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant chemotherapy and irradiation
Trial: 6268269
Drug: Delayed chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed chemotherapy following radiotherapy recurrence
Trial: 6268269
Drug: Chemotherapy groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy groups
Trial: 6268269
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of irradiation
Trial: 31449577
Drug: Platform-switched implant
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platform-switched implant
Trial: 31449577
Drug: Platform-matched implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platform-matched implant
Trial: 23721147
Drug: Intensity-modulated radiotherapy
RxNorm normalized name: California intense cedar pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity-modulated radiotherapy (IMRT) with simultaneous-integrated boost and weekly cisplatin 40 mg/m² (median 6 cycles)
Trial: 21855223
Drug: Acute nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute nicotine administration (placebo, low, or high dose nicotine patch)
Trial: 21855223
Drug: Non-smoking controls
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-smoking controls (placebo or low dose)
Trial: 21855223
Drug: Acute nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute nicotine administration
Trial: 19151048
Drug: Levosimendan (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (24 microg kg(‐1) administered as a slow i.v. bolus over 10 min)
Trial: 10841002
Drug: Insulin glargine[15]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin glargine[15]
Trial: 10841002
Drug: Insulin glargine[80]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin glargine[80]
Trial: 10841002
Drug: Insulin glargine[30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin glargine[30]
Trial: 10174312
Drug: Tiludronic acid
RxNorm normalized name: tiludronic acid
DrugBank: Tiludronic acid (DB01133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiludronic acid (400 mg/day)
Trial: 6584449
Drug: Calcium (1
RxNorm normalized name: hydroxyapatite 275 mg calcium (1,100 mg) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1 g) daily for 180 days
Trial: 6584449
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets daily for 180 days
Trial: 12891225
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg aprepitant on day 1 and then 80 mg/d on days 2 to 5
Trial: 12891225
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg aprepitant on day 1 and then 25 mg/d on days 2 to 5
Trial: 525982
Drug: Levamisole (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (three different doses)
Trial: 28086848
Drug: Parents as
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parents as Agents of Change (PAC©) intervention, a manualized, 16-session, group-based, health care professional-led intervention for parents
Trial: 25120110
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (GTE) supplementation (980 mg polyphenols daily)
Trial: 16827252
Drug: Buprenorphine 30
RxNorm normalized name: BUPRENORPHINE 300MCG BUCCAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 30 micrograms with hyperbaric bupivacaine 0.75% 2 ml (group B)
Trial: 16827252
Drug: Fentanyl 10
RxNorm normalized name: FENTANYL 100MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 10 micrograms with hyperbaric bupivacaine 0.75% 2 ml (group F)
Trial: 16827252
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 0.75% 2 ml (group L control)
Trial: 12811695
Drug: CT-guided intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-guided intra-articular corticosteroid injection (low-dose injection)
Trial: 12811695
Drug: NSAIDs therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs therapy
Trial: 7762835
Drug: Fentanyl 50
RxNorm normalized name: fentanyl 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 50 micrograms and propofol 35 mg (FP)
Trial: 7762835
Drug: Fentanyl 50
RxNorm normalized name: fentanyl 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 50 micrograms and midazolam 2 mg (FM)
Trial: 7762835
Drug: Fentanyl 50
RxNorm normalized name: fentanyl 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 50 micrograms, midazolam 2 mg, and propofol 35 mg (FMP)
Trial: 7762835
Drug: Alcohol 56
RxNorm normalized name: ALCOHOL 56 mg in 1 g TOPICAL SPRAY [CVS Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol 56 g (orally administered)
Trial: 2113967
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg DOPS
Trial: 2113967
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg DOPS
Trial: 105656
Drug: Low-dose insulin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose insulin regimen (0.44 U/kg body weight loading dose half intramuscularly and half intravenously followed by 7 U/h intramuscularly)
Trial: 105656
Drug: Constant infusion
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant infusion of 7 U/h in albumin-free saline (0.44 U/kg loading dose intravenously)
Trial: 26880570
Drug: DAPT interruption
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT interruption (aspirin only)
Trial: 21223673
Drug: Auricular acupuncture
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular acupuncture therapy (AAT) on active points
Trial: 16415999
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil 5 mg
Trial: 16415999
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil 20 mg
Trial: 16415999
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil 40 mg
Trial: 16415999
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil 60 mg
Trial: 7538555
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) 5 micrograms/kg/d beginning on day + 1 following transplant
Trial: 7538555
Drug: G-CSF in
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF in patients who received PBSC alone
Trial: 7538555
Drug: G-CSF in
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF in patients who received PBSC with bone marrow
Trial: 2157240
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose proton treatment
Trial: 27977473
Drug: Bremelanotide 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bremelanotide 1.25 mg
Trial: 10873400
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy using radiation alone
Trial: 8249563
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of morphine in saline
Trial: 2411072
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 10% zinc sulfate in Aquaphor ointment
Trial: 18612188
Drug: Fluvastatin, 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin, 80 mg/day, orally for 6 weeks
Trial: 16037178
Drug: RM group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RM group (0.25% ropivacaine and morphine 0.2 mg/mL)
Trial: 16037178
Drug: RMK group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RMK group (0.25% ropivacaine, morphine 0.2 mg/mL and ketorolac 1 mg/mL)
Trial: 11922560
Drug: Budesonide 9
RxNorm normalized name: budesonide 9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 9 mg once daily (n = 93)
Trial: 11922560
Drug: Mesalazine 2
RxNorm normalized name: mesalazine 2 GM per 59 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine 2 g b.i.d. (n = 89)
Trial: 11922560
Drug: Mesalazine 2
RxNorm normalized name: mesalazine 2 GM per 59 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine 2 g b.i.d.
Trial: 8780276
Drug: Intravenous buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous buprenorphine 2 micrograms/kg
Trial: 8780276
Drug: Intravenous buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous buprenorphine 4 micrograms/kg
Trial: 1632979
Drug: Natural leukocyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural leukocyte alpha interferon (IFN) administered at 6 MU i.m. daily for 4 weeks and thereafter 3 times per week for 2 months, combined with radiotherapy (2 Gy daily, 5 fractions per week)
Trial: 6708391
Drug: Digoxin administration
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin administration (plasma levels 1.55 +/‐ 0.27 ng/ml) lasting 35 days
Trial: 6708391
Drug: Digoxin administration
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin administration with maximal stimulation of adrenal and gonadal glands by ACTH and hCG
Trial: 6708391
Drug: Digoxin administration
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin administration over a period of 150‐210 days
Trial: 26363127
Drug: Demands and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demands and Capacities-based treatment
Trial: 26363127
Drug: Lidcombe Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidcombe Program and Demands and Capacities-based treatment
Trial: 9640080
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ZPP measurement with ferritin and peripheral blood morphology
Trial: 8102829
Drug: Vecuronium doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium doses ranging from 0.1 to 0.3 mg kg‐1
Trial: 3813189
Drug: Urapidil (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil (0.75 mg/kg)
Trial: 3813189
Drug: Hydralazine (0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine (0.35 mg/kg)
Trial: 28750894
Drug: Capsule and
RxNorm normalized name: COMBINATION PACKAGE, CAPSULE AND PAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule and disc shaped printlets
Trial: 23041092
Drug: vWF >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vWF > 1434.92 mU/ml
Trial: 15106359
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (calcium 1000 mg/day)
Trial: 11334476
Drug: EE35/CPA (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE35/CPA (2.0 mg cyproterone acetate and 35 microg ethinylestradiol for 21 days)
Trial: 9127977
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity intervention (twice-weekly sessions of low intensity movements for one year)
Trial: 26340656
Drug: Light-touch sham
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light-touch sham treatment
Trial: 25258523
Drug: IG/HD +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IG/HD + RCH (210 g of ricotta cheese daily)
Trial: 22682721
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg orally 24 hours prior to abortion
Trial: 15753242
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) combined with pharmacotherapy
Trial: 11388815
Drug: Home service
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home service (automatic transmission of blood pressure data, computerized report forms, weekly electronic transmission)
Trial: 3326920
Drug: Captopril plus
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril plus Nifedipine (50 mg and 20 mg twice daily respectively)
Trial: 19214122
Drug: 3% SPL7013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% SPL7013 gel (n = 24)
Trial: 19214122
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (n = 12)
Trial: 19214122
Drug: SPL7013 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPL7013 gel
Trial: 17237130
Drug: Carvedilol (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (n = 1511, target dose 50 mg daily)